THE DEAL, AT A GLANCE
From the announcementOak Hill Bio
What it doesOak Hill Bio is a Digital Health company focused on advance rugonersen for Angelman syndrome.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Who is involvedBacked by TakedaFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedOak Hill Bio raised $32.5M Series A, announced 2026-06-01From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersOak Hill Bio's Series A financing supports a focused healthcare and life sciences plan to advance rugonersen for Angelman syndrome.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Oak Hill Bio · Financing Record
Explore source-linked visual explanations for Oak Hill Bio. Unsupported claims are withheld while source review continues.
Record 5028 · Recorded date: 2026-06-01
Explore company records →